Volume 14, Issue 4 (July & August 2023)
BCN 2023, 14(4): 501-510 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohamed A S, Ahmad H M, Abdelrahman A A, Aly U F, Khaled K A. Therapeutic Impacts of Hyperbaric Oxygen Therapy and Risperidone on Children with Autism: A Clinical Trial. BCN 2023; 14 (4) :501-510
URL: http://bcn.iums.ac.ir/article-1-2030-en.html
URL: http://bcn.iums.ac.ir/article-1-2030-en.html
1- Department of Clinical Pharmacy, Faculty of Pharmacy, Deraya University, Minia, Egypt.
2- Department of Internal Medicine and Biomedical Chemistry, Egypt Ministry of Health and Population, Minia, Egypt.
3- Department of Neuropsychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt.
4- Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
2- Department of Internal Medicine and Biomedical Chemistry, Egypt Ministry of Health and Population, Minia, Egypt.
3- Department of Neuropsychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt.
4- Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, Egypt.
Abstract:
Introduction: In this research, we investigated any possible effect of receiving hyperbaric oxygen therapy (HBOT) or risperidone on the core symptoms of autism in children diagnosed with autism spectrum disorder (ASD).
Methods: This study was a randomized, controlled clinical trial in Minia and Assiut University hospitals in Egypt with three parallel groups. One hundred and eighty children with autism, aged 5–8 years were divided into three equal groups (n=60). Group 1 (G1) received 40 sessions of HBOT within two months, group 2 (G2) received risperidone (dose: 0.25 mg per day in children weighing less than 20 kg and 0.5 mg per day in cases weighing more) for six months, and group 3 (G3) as the control group, received a placebo for six months. The assessment was done using childhood autism rating scale (CARS) and autism treatment evaluation checklist (ATEC) at the beginning of the study (baseline) and after one year.
Results: The mean total CARS and ATEC scores significantly decreased (improved) by varying degrees in the three groups after a year of follow-up compared to the baseline scores, but the best results were found in G1, G2, and G3, respectively.
Conclusion: Using HBOT or risperidone is effective in treating the core symptoms of autism in children diagnosed with autism spectrum disorder, but using HBOT gives better results than risperidone therapy.
Methods: This study was a randomized, controlled clinical trial in Minia and Assiut University hospitals in Egypt with three parallel groups. One hundred and eighty children with autism, aged 5–8 years were divided into three equal groups (n=60). Group 1 (G1) received 40 sessions of HBOT within two months, group 2 (G2) received risperidone (dose: 0.25 mg per day in children weighing less than 20 kg and 0.5 mg per day in cases weighing more) for six months, and group 3 (G3) as the control group, received a placebo for six months. The assessment was done using childhood autism rating scale (CARS) and autism treatment evaluation checklist (ATEC) at the beginning of the study (baseline) and after one year.
Results: The mean total CARS and ATEC scores significantly decreased (improved) by varying degrees in the three groups after a year of follow-up compared to the baseline scores, but the best results were found in G1, G2, and G3, respectively.
Conclusion: Using HBOT or risperidone is effective in treating the core symptoms of autism in children diagnosed with autism spectrum disorder, but using HBOT gives better results than risperidone therapy.
Keywords: Autism, Autism treatment evaluation checklist, Childhood autism rating scale, Hyperbaric oxygen therapy, Risperidone
Type of Study: Original |
Subject:
Clinical Neuroscience
Received: 2020/12/14 | Accepted: 2021/07/3 | Published: 2023/07/1
Received: 2020/12/14 | Accepted: 2021/07/3 | Published: 2023/07/1
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright © The Author(s);
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
